New Treatment Option for Patients With Advanced NSCLC, EGFR Mutations: Presented at ELCC

By Jenny Powers

GENEVA -- April 12, 2019 -- Adding atezolizumab to bevacizumab and standard chemotherapy with carboplatin and paclitaxel improved overall survival (OS) in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) and EGFR mutations who have failed prior treatment with tyrosine kinase inhibitors (TKIs), according to a study presented here at the 2019 European Lung Cancer Conference (ELCC).

“IMpower150 is the first phase 3 immunotherapy-based combination study to demonstrate a statistically significant and clinically meaningful improvement in OS in patients with metastatic nonsquamous NSCLC and EGFR-mt, providing a potential new standard of care for these patients,” said Martin Reck, MD, Lung Clinic Grosshansdorf, Grosshansdorf, Germany.

Overall survival among patients who received atezolizumab and bevacizumab plus chemotherapy has not been reached, compared with 18.7 months for patients who received bevacizumab plus chemotherapy.

IMpower150 enrolled 1,202 patients who were randomised equally to receive atezolizumab 1,200 mg plus carboplatin and paclitaxel (arm A) or to atezolizumab plus bevacizumab 15 mg/kg plus chemotherapy (arm B), or to bevacizumab plus chemotherapy (arm C).

The agents were administered every 3 weeks for 4 or 6 cycles per investigator decision, followed by maintenance with atezolizumab plus bevacizumab or single agent atezolizumab or bevacizumab, respectively.

“The trial explored these combinations because atezolizumab inhibits PD-L1 to restore anticancer immunity and may be enhanced through bevacizumab’s inhibition of VEGF immunosuppression and by promoting T-cell tumour infiltration, while the chemotherapy of carboplatin plus paclitaxel may induce immune responses,” said Dr. Reck.

He presented findings here today from an exploratory analysis of patients with EGFR-mutant disease who had received prior TKI therapy.

“Adding atezolizumab to standard-of-care bevacizumab and chemotherapy provided survival benefit in patients with EGFR mutations who have failed previous TKIs,” said Dr. Reck. “This regimen may represent a new treatment option for this patient population.”

[Presentation title: IMpower150: An Exploratory Analysis of Efficacy Outcomes in Patients With EGFR Mutations. Abstract 104O]

To read more Conference Dispatch articles, click here.